MiMedx Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDXG research report →
Range $7 – $8
Price Chart
About the company
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue.
- CEO
- Joseph H. Capper
- IPO
- 2008
- Employees
- 808
- HQ
- Marietta, GA, US
Get TickerSpark's AI analysis on MDXG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $445.07M
- P/E
- -23.46
- Fwd P/E
- 152.50
- PEG
- 0.16
- P/S
- 1.47
- P/B
- 2.11
- EV/EBITDA
- -22.32
- Div Yield
- 0.00%
- Gross Margin
- 77.29%
- Op Margin
- -8.28%
- Net Margin
- -6.32%
- ROE
- -8.29%
- ROIC
- -9.73%
Latest fiscal year · YoY change
- Revenue
- $418.63M+20.0%
- Gross Profit
- $345.62M+19.7%
- Op Income
- $63.89M
- Net Income
- $48.58M+14.5%
- EPS
- $0.33+13.8%
- OCF Growth
- +11.8%
- FCF Growth
- +13.1%
- 52W High
- $7.45
- 52W Low
- $3.03
- 50D MA
- $4.14
- 200D MA
- $4.13
- Beta
- 1.42
- RSI (14)
- 23
- Avg Volume
- 1.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MiMedx posted a sharp sequential recovery in profitability on strong Surgical growth, while Wound Care remained under pressure from Medicare reimbursement changes and the Sanara acquisition faced an FTC delay.· October 28, 2026
- Net sales were $62 million; Surgical revenue rose 9% year over year to $40 million, while Wound net sales fell 71% year over year to $22 million.
- Gross margin improved to 80% from 84% a year ago and was about 11 points better than Q2, helped by cost cuts and manufacturing efficiencies.
- Adjusted EBITDA returned to positive at $2 million, a roughly $10 million sequential improvement, and management said it achieved positive adjusted EBITDA and cash flow for the first time this year.
- Wound Care Centers showed signs of stabilization with volume up more than 20% year over year and 7% sequentially, but management said the reimbursement reset is still working through the market.
- MiMedx updated full-year 2026 net sales guidance to $250 million to $260 million and expects modest sequential adjusted EBITDA growth in Q4.
Third-quarter 2026 net sales were $62 million, down 45% year over year. Surgical net sales were $40 million, up 9% year over year and 2% sequentially; management said Surgical volume grew in the mid-teens. Wound net sales were $22 million, down 71% year over year. Gross profit was $50 million versus $95 million a year ago, and gross margin was 80% versus 84% a year ago; management said Q3 gross margin improved by about 11 percentage points sequentially from Q2. GAAP net loss was $9 million, or $0.06 per share, versus GAAP income of $17 million, or $0.11 per share, last year. Adjusted net loss was $1 million, or $0.01 per share, versus adjusted net income of $23 million, or $0.15 per share, last year. Adjusted EBITDA was $2 million, or 3% of net sales, versus $35 million, or 31% of net sales, a year ago, but improved by about $10 million sequentially. For Q4, management expects Surgical to grow in the high single digits year over year, Wound to grow mid-single digits sequentially, gross margin to approximate Q3 levels, sales and marketing expense at 58% to 60% of net sales, GAAP G&A of about $18 million to $19 million, R&D of about $3 million to $3.5 million, and modest sequential adjusted EBITDA growth. Full-year 2026 net sales are now expected to be $250 million to $260 million.
Joe Capper said the quarter reinforced MiMedx’s strategic shift toward Surgical, which delivered mid-teens volume growth and continued broad-based demand across the portfolio. He emphasized that Wound Care is still navigating the reset from 2026 Medicare reimbursement changes, but said Wound Care Centers are a relative strength and that the company expects to benefit when the market stabilizes. He was upbeat on the Sanara deal, saying it fits the company’s strategy, would be accretive immediately, and would accelerate the move toward a more Surgical-heavy mix.
Doug Rice focused on the financial reset and cost actions, noting that the company returned to positive adjusted EBITDA on a stand-alone basis and ended the quarter with $121 million in net cash, up $2 million sequentially and essentially flat year over year. He highlighted the payoff of the remaining $17 million principal on the Citizens Term Loan, leaving no borrowings outstanding under term loan or revolver facilities. He also said fourth-quarter gross margin should approximate Q3 levels, sales and marketing should be 58% to 60% of net sales, G&A about $18 million to $19 million, and R&D about $3 million to $3.5 million. On Sanara, he cited the $300 million Hayfin term loan commitment and said the combined company is expected to produce close to $400 million of run-rate revenue, at least $20 million of annualized synergies, and at least a 20% adjusted EBITDA margin in the first full year after closing.
Analysts pressed on the Q3 Surgical rebate activity and whether it would recur; management said it reflected short-term promotional work and a few accounts that unexpectedly reached targets, and said there should be less noise in Q4. Questions on the FTC second request and Sanara timing drew a cautious answer: management said discussions with the FTC have been positive, but they would not provide a timeline and said they remain fully committed to the acquisition. Analysts also asked about the pace of Wound stabilization and whether more evidence-generation spend was still necessary; management said the reset is only three quarters old, visibility is limited, and the company remains committed to clinical studies, including two active randomized controlled trials.
The strongest bull case from the call is that Surgical momentum appears intact even without one-off sales, with broad-based growth, mid-teens volume expansion, and new product launches and 510(k) submissions in progress. Management also argued that the cost reset is working: gross margin rebounded sharply, adjusted EBITDA turned positive, and the balance sheet is debt-free with $121 million in net cash.
The main bear case is that Wound Care remains under significant pressure from Medicare reimbursement changes, with sales down 71% year over year and management still unable to say when the market will stabilize. The Sanara acquisition, while strategically important, is delayed by an FTC second request, which adds timing uncertainty and a modest ticking fee, and management acknowledged they cannot control the closing timeline.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.4%
- Shares Outstanding
- 145.93M
- Float Shares
- 114.43M
of shares held by institutions
230 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MDXG, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Tom MalinowskiHouse · NJ07 | Sell | May 30, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Essex Woodlands Management, Inc. | 28.20M | 0 |
| Blackrock, Inc. | 13.01M | ▲ 852.87K |
| Trigran Investments, Inc. | 7.39M | ▲ 217.56K |
| Vanguard Group Inc | 7.18M | ▲ 382.62K |
| Nantahala Capital Management, LLC | 6.91M | ▲ 2.14M |
| Vanguard Capital Management LLC | 5.16M | ▼ 27.91K |
| Paradigm Capital Management Inc/Ny | 4.56M | ▲ 482.20K |
| State Street Corp | 4.41M | ▼ 1.17M |
| Geode Capital Management, LLC | 3.15M | ▲ 4.31K |
| Goldman Sachs Group Inc | 2.67M | ▲ 1.48M |
| Aqr Capital Management LLC | 2.47M | ▲ 1.55M |
| Renaissance Technologies LLC | 2.37M | ▼ 75.20K |
Held by 176 ETFs
Biggest fund positions in MDXG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | DOUG RICE | other | 12,749 |
| Jun 24, 26 | Maersk-Moller Kimberly | other | 19,820 |
| Jun 10, 26 | BIERMAN JAMES L | other | 50,913 |
| Jun 10, 26 | PUHY DOROTHY E | other | 50,913 |
| Jun 10, 26 | Newton Todd | other | 50,913 |
| Jun 10, 26 | HAWKINS WILLIAM A | other | 50,913 |
| Jun 10, 26 | Olson Tiffany | other | 50,913 |
| Mar 13, 26 | Hulse William Frank IV | other | 20,245 |
| Mar 13, 26 | Maersk-Moller Kimberly | other | 6,762 |
| Mar 10, 26 | Maersk-Moller Kimberly | other | 42,845 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDXG coverage
Recent articles, reports, and earnings notes.

Should You Buy the BioStem Technologies IPO? Here's the Setup
BioStem Technologies, Inc. (NASDAQ: BSEM) is expected to list on 2026-08-07, but the price range has not been disclosed. The company is coming to market through an expected Nasdaq uplisting rather than a traditional IPO prospectus. The bull case is a high-margin wound-care platform; the bear case is heavy customer concentration and a 2025 revenue drop.

Conexeu Sciences Inc. IPO: What to Know Before It Lists
Conexeu Sciences Inc. (NASDAQ: CNXU) is expected to list on 2026-05-21, with the price range not yet disclosed. The setup is a preclinical regenerative medicine story with no FDA-cleared product yet, so shareholders should watch for pricing, dilution, and how the market values the pipeline risk.
Want a deeper read on MDXG?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles
defenseworld.net · Nov 17
MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles
marketbeat.com · Nov 15
MIMEDX to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 6
What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
globenewswire.com · Oct 28
MIMEDX Announces $25 Million Patent License Agreement
globenewswire.com · Oct 28
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
defenseworld.net · Oct 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.